^
    Back
    Association details:
    Biomarker:NFE2L2 mutation
    Cancer:Solid Tumor
    Drug:IPN60090 (Glutaminase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

    Excerpt:
    ...Patients with tumors harboring actionable KEAP1/NFE2L2/STK11/NF1 mutations Patients with low ASNS expression levels (HGSOC or endometrial cancer) Patients who had immunotherapy (IO) melanoma (Minimum treatment duration of prior PD-1 or PD-L1-containing regimen of 12 weeks [or equivalent of 2 response evaluations])....
    Trial ID:
    NCT05039801
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Technology Networks
    Title:

    New Therapy for Lung and Ovarian Cancer Advances to Early-stage Clinical Development

    Published date:
    04/27/2020
    Excerpt:
    IPN60090 currently is under investigation in a Phase I dose-escalation and dose-expansion study for patients with advanced solid tumors that harbor KEAP1/NFE2L2 mutations or have low ASNS levels. Initial data from the clinical trial indicate that IPN60090 is effectively inhibiting GLS1 activity in peripheral blood.mononuclear cells from patients.